ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
October 05, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
September 23, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREEMONT, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in...
ABVC Biopharma Announces Letter to Shareholders
September 13, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Sept. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
September 09, 2022 08:30 ET
|
ABVC BioPharma, Inc.
New Australia Site Confirmed to Participate in the Study FREMONT, CA, Sept. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
ABVC Provides Oncology Pipeline Updates
August 22, 2022 08:30 ET
|
ABVC BioPharma, Inc.
Phase II Clinical Trial for Pancreatic Cancer Planned for Q2 2023 FREMONT, CA, Aug. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage...
ABVC BioPharma Provides Vitargus® Update
August 18, 2022 08:30 ET
|
ABVC BioPharma, Inc.
Phase II Vitargus® Clinical Trial Receives Local Ethics Committee Approval in Thailand FREMONT, CA, Aug. 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
August 15, 2022 17:48 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Provides Vitargus® Update
August 02, 2022 08:30 ET
|
ABVC BioPharma, Inc.
Phase II Vitargus® Clinical Study Protocol Receives Local Ethics Committee Approval FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a...
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028
July 18, 2022 08:30 ET
|
ABVC BioPharma, Inc.
-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage...
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
July 13, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...